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CObjective: Health technology assessments (HTAs) intend to inform
real-world decisions. They often draw on data from explanatory trials
and hence are not always applicable to the decision problem. HTAs
may therefore not meet the needs of decision makers. Our objective
was to develop and apply a checklist to: 1) systematically frame HTAs
in a way that they are applicable to the decision problem; and 2) assess
if a decision problem can be informed by an available HTA.
Methods: We reviewed published literature to identify factors that
should be considered when framing HTAs for resource allocation deci-
sions. The checklist was finalized in collaboration with clinicians and
policy makers. We applied the checklist to the economic evaluation of
trastuzumab in early breast cancer.We defined a reference case and for
each study, retrieved through a systematic review, we examined if
each factor was explicitly considered. Results: A checklist was devel-
oped with 11 factors (e.g., clinical practice, consequences, and patient O
ivers
al So
doi:10.1016/j.jval.2011.01.005use). In the case of trastuzumab, most factors were considered by the
11 retrieved economic evaluations. Two factors, being the inclusion of
all relevant comparators and professional use, were considered by
none of the studies. Conclusions: We developed a comprehensive
hecklist with 11 factors to frame HTAs and to assess the applicability
f HTAs to resource allocation decisions. Economic evaluations on tras-
uzumab considered some of these factors, but overlooked others. The
roposed checklist assists in systematically considering all factors in
eveloping the conceptual model of an HTA, to make HTAs better re-
ect the decision problem.
eywords: breast cancer, cost-effectiveness, decision making, eco-
omic evaluation, evidence-based medicine.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Recently, the Centers for Medicare and Medicaid Services (CMS)
decided not to reimburse computed tomographic colonography in
the United States. The decision makers at CMS emphasized the
lack of applicability of the evidence to the decision problem be-
cause themean age of the trial participants was lower than that of
the actual patient population [1]. Indeed, more and more technol-
ogies are not reimbursed because the health technology assess-
ment (HTA) is not applicable to the decision problem [2]. Or, after a
umber of years technologies turn out to be wrongfully reim-
ursed [3]. In this article we describe the development and appli-
ation of a checklist to systematically frame HTAs for resource
llocation decisions in a way that they are applicable to the deci-
ion problem.
One of the key principles to improve the use of HTA for re-
ource allocation decisions is that the scope of the HTA should be
elevant to its use [4,5]. HTA involves synthesis of evidence, and
his evidence should be relevant to the decision. When designing
n HTA, one of the first steps is the framing of the study, also
* Address correspondence to: Janneke P.C. Grutters, Maastricht Un
Box 616, 6200 MD Maastricht, The Netherlands.
E-mail: j.grutters@maastrichtuniversity.nl.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.referred to as the development of a conceptual model [6,7]. It is
crucial that the conceptual model actually represents the decision
problem; this is referred to as conceptual model validity [8,9]. To
avoid withholding patients effective treatment, resource alloca-
tion decisions are often made directly after the efficacy of the
intervention is shown in a trial [10]. As a result HTAs that are
performed to inform these decisions are often based on data col-
lection alongside these trials. It is well known that trial results do
not necessarily reflect the real world [11,12]. For instance, patient
mix, compliance, and cointerventions are known to differ sub-
stantially between trial and daily practice [13]. Earlier research
showed that although it has a large influence on effectiveness and
cost-effectiveness, only few analyses incorporate suboptimal pa-
tient compliance [13,14]. As a result, the relative effectiveness and
cost-effectiveness of a new technology in practice can be substan-
tially different from that observed in trials [11,12].
Although the prerequisite of applicability to the decision prob-
lem is well known and accepted, in practice the development of
the conceptual model of HTAs often seems to be strongly influ-
enced by the availability of data [15,16]. This may result in a low
conceptual model validity [17].
ity, Department of Health Organization, Policy, and Economics, PO
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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778 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 7 7 – 7 8 4Handbooks on economic evaluation provide a guidance onhow
to frame an HTA, but do not pay explicit attention to the fact that
trial evidence may not be directly applicable to the decision prob-
lem [6,7]. In the critical assessment of an HTA two questions are
relevant: 1) Is the methodology appropriate and the results valid;
and 2) are the results applicable to the decision problem [10]. Com-
prehensive checklists exist to answer the first question, assessing
the quality of the HTA [8,10,18,19]. No checklists exist to answer
the second question, assessing the applicability of the HTA to the
decision problem [8]. Although the issue of applicability is ac-
knowledged, it is said to be difficult to evaluate this in any formal
way [8]. In this study we aim to provide a helpful tool for this
evaluation. Our objectivewas two-fold. First, to develop a checklist
to frame HTAs in a way that they are applicable to the decision
problem. The checklist can both guide the design and analysis of
an HTA for resource allocation decisions and assess if a specific
decision problem can be informed by an existing HTA. It can then
function as a guide to which factors should be adapted tomake an
existing HTA applicable to the decision problem. Second, we illus-
trate the use of the checklist by assessing if economic evaluations
of trastuzumab in early stage breast cancer explicitly consider
factors thatmay hamper the applicability of results to the decision
problem. We used this example because of the availability of a
number of economic evaluation studies and the availability of
data from randomized controlled trials [20].
Methods
Framing an HTA
When framing an HTA, one needs to be aware of the applicability
of the study to the decision problem. This awareness will enhance
the conceptual model validity and may increase use of the results
for decisionmaking. Two handbooks describe the process of fram-
ing an HTA [6,7]. First, the objective, audience, and perspective of
the analysis should be defined. Further, the population, interven-
tion, and comparators need to be specified. Also, the time horizon
and boundaries of the analysis should be defined, as should the
type of analysis. Although sometimes in this process authors im-
plicitly state that one should evaluate the intervention as it will be
used in daily practice, this is not made explicit.
Checklist development
To develop the checklist we used the process of framing anHTA as
described above as a starting point. In addition, we reviewed pub-
lished literature and handbooks to identify factors that can influ-
ence the applicability of HTAs for real-world resource allocation
decisions. Because we examine if trial evidence is directly appli-
cable to the decision problem, in our review we focused on the
generalizability of scientific evidence. The Cochrane library,
PubMed, and MEDLINE database were searched until March 2010.
The search included the following terms: (“Randomized Con-
trolled Trials as Topic” [MeSH Terms] OR “Clinical Trials as Topic”
[MeSH Terms]) and (“generalizability” OR “generalisability” OR
“real world”). Based on the title, abstract, and if necessary the full
article, studieswere included if theywerewritten in English, had a
methodological focus, and provided a list of issues that could af-
fect the applicability of scientific evidence.We also included three
frequently used handbooks on general, model-based, and trial-
based economic evaluation [10,21,22]. Issues that could influence
the applicability of HTAs to the decision problem were identified
by two authors (Grutters and Joore) independently and listed per
source. Overlapping factors were clustered. Both the clustering of
the factors and the development of the final checklist were dis-
cussed with clinicians (Tjan-Heijnen, Seferina, and Van Kampen)
and policy makers (Goettsch) during consensus meetings. The cli- bnicians were chosen because of their expert knowledge of breast
cancer and trastuzumab treatment in particular. The policymaker
was chosen based on his longstanding experience with the use of
HTAs for resource allocation decisions.
Application to the case of trastuzumab
Breast cancer is themost common type of cancer inwomenworld-
wide [23].Womenwith human epidermal growth factor receptor 2
(HER2) positive breast cancer have a poor prognosis after diagnosis
if not treated with HER2-targeted therapy [24]. Trastuzumab is a
humanized monoclonal antibody that binds to HER2. Recent ran-
domized controlled trials have shown a positive treatment effect
of trastuzumab in women with HER2 positive early breast cancer
[25–30]. This has resulted in a number of economic evaluations
that are all based on these randomized controlled trials [20]. Tras-
uzumab is therefore deemed a suitable case to examine if the
hecklist is useful in assessing if efforts were made to make the
conomic evaluation applicable to the real-world decision prob-
em.We examined if economic evaluation studies on trastuzumab
n early breast cancer explicitly considered all factors of the check-
ist in framing their economic evaluation. For this purpose we first
ad to define a reference case. In close collaboration with clini-
ians and decision makers we framed the economic evaluation of
rastuzumab in early breast cancer to define this reference case.
Next, a systematic literature review was performed to identify
riginal HTAs of trastuzumab in HER2 positive early breast cancer.
or illustration purposes we limited the search to economic eval-
ations. We used the electronic databases Cochrane library,
ubMed, and MEDLINE to search for peer-reviewed full articles,
ublished before March 2010. The search included the following
erms: (“trastuzumab” OR “herceptin”) and (“breast cancer”) and
“cost-effectiveness” OR “economic evaluation”). Additional refer-
nces were searched through manual searches of the reference
ists and specialist journals. Studies were included only if they
ere written in English and focused on early breast cancer. A data
xtraction tool to extract relevant information from each included
tudy was developed and used by two authors (Grutters, Joore)
ndependently. Both authors completed the data extraction tool
or all studies. Discrepancies were solved in consensus meetings
ith the other authors (Tjan-Heijnen, Seferina, and Van Kampen).
Results
Results of the literature search
The first literature search identified 882 articles. After checking
the inclusion criteria five peer-reviewed articles were included:
a comprehensive HTA report on generalizability [31] and four
other publications [11,12,32,33]. Five handbooks were included
6,7,10,21,22]. Because three handbooks [10,21,22] named issues
hat were reasons to use modelling instead of trial-based eco-
omic evaluation, we additionally included a comprehensive ar-
icle that concerns the reasons for using model-based economic
valuation [34] (see Table 1 for an overview of the issues we de-
ived from each source).
As was mentioned in the Methods section, two handbooks
entioned the objective, audience, and perspective, which can
ffect the applicability of an HTA [6,7]. Issues concerning patient
ix [11,31,32], population [6,7,33,34], patient selection [12], and
epresentative sample [22] were clustered. A fifth issue, listed in
lmost all sources, concerned the comparators [6,7,10,11,21,22,31–
4]. Issues regarding the intervention [6,7], clinical practice
11,22,33], and differences between trial protocol and routine prac-
ice [12,32,34] all relate to clinical practice, and were therefore
lustered. The time horizon of the analysis was mentioned in all
ut one of the sources [6,7,10-12,21,22,32–34]. The issues analysis
Table 1 – Results of the literature review on issues that should be considered when framing an HTA: identified issues in each source.
Gold (6) Fox-Rushby
(7)
Sculpher (31) Revicki (11) Rothwell (12) Baltussen (32) O’Brien (34) Garrison
(33)
Drummond
(10)
Briggs (21) Glick (22)
1. Objective Objective
2. Audience Audience
3. Perspective Perspective
4. Population Population Patient mix Patient mix Patient selection Patient mix Patient
population
Study
population
Representative
sample
5. Comparators Comparators Clinical practice
(availability,
comparators)
Comparators Artificial design/
interactions
with other
diseases
Comparators Comparators Comparators Comparators Comparators
6. Intervention Intervention Clinical
practice
Differences between
trial protocol and
routine practice
Protocol-driven
costs &
outcomes
Clinical
practice
Clinical
practice/
settting
7. Time horizon Horizon Time
horizon
Time horizon Time horizon Time horizon Time horizon Time horizon Time horizon Time horizon
8. Analysis type Endpoints Outcome measures External effects Measurement
of outcomes
Types of
outcomes
Endpoints Outcome
measure
Boundaries Sample size Sample size
9. Compliance Compliance Compliance Compliance
10. Skills/experience Physician
characteristics
Selected
provider
population
Belief/incentives
Education/training Learning effects
11. Price/resource use Resource use Setting of the trial Health service
characteristics
Price
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780 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 7 7 – 7 8 4type [6], endpoints [10,11], and outcomes [12,22,32–34] were clus-
tered as they all relate to consequences. Other clusters of issues
were boundaries [6], sample size [22,34], and compliance [11,31–
33]. In the cluster of issues related to physician characteristics [32]
r the provider population [34] we included skills/experience [31],
eliefs [31], and training or learning effects [31,32]. Finally, issues
regarding price/resource use [11,31] were clustered with issues on
etting [12] and health service characteristics [32].
Checklist development
Each cluster of issues was converted into one factor in the check-
list. Boundaries of the HTA can concern consequences (e.g., ripple
effects) or patient population (which patients are considered in
the analysis?). Sample size is also related to the consequences
cluster. Therefore, boundaries and sample size are already covered
in the factors consequences and patient population. The clusters re-
garding compliance and physician characteristics were defined
more broadly as patient use and professional use, respectively.
This resulted in a final checklist with eleven factors: objective,
audience, perspective, population, comparators, clinical practice,
time horizon, consequences, patient use, professional use, and
price and resource use (Table 2).
Table 2 – Checklist to frame HTAs to the decision
problem.
Factor Question
1. Objective How will the HTA be used?
(e.g., contribute to evidence, inform
adoption decision)
2. Audience What is the audience (principal users) for
the HTA?
(e.g., government, pharmaceutical
companies, insurance companies, patient
groups, jurisdiction)
3. Perspective Which viewpoint or perspective is relevant
for the HTA?
(e.g., societal, health care, insurer, payer)
4. Population What is the patient population relevant for
the decision problem?
(e.g., age, health status, sex, other
characteristics)
5. Comparators What are relevant comparators for the
decision problem?
(e.g., care as usual, alternative
technologies)
6. Clinical practice How are the technologies embedded in
clinical practice?
(e.g., diagnostics, clinical instead of
research protocol)
7. Time horizon Which time horizon is relevant for the
decision problem?
(e.g., lifetime, one year)
8. Consequences Which consequences are relevant for the
decision problem?
(e.g., final versus intermediate outcomes,
indirect and/or rare consequences)
9. Patient use What is the patient use that is relevant for
the decision problem?
(e.g., uptake, compliance, adherence)
10. Professional use What is the use of the technology by
health care professionals that is relevant
for the decision problem?
(e.g., skills, experience, beliefs)
11. Price and
resource use
What price level and resource use are
relevant for the decision problem?
(e.g., personnel providing the
intervention)Besides the objective, audience, and perspective of the HTA
6,7], the patient population may also affect the applicability of an
TA. In defining the population it is important to be aware that, as
rials often apply strict in- and exclusion criteria, the population in
trial may differ from the population that is relevant to the deci-
ion problem [11,12,22,31–35]. Trials often compare a new inter-
ention to care as usual or placebo. As a result, comparative treat-
ents relevant to the decision problemmaywell be different from
he direct comparisons available in the scientific evidence
10,11,21,22,31,33,34]. It is therefore important to consider all rel-
vant comparators in an HTA. Clinical practice may well differ
rom the restricted trial setting (11,12,22,31–34]. For example, an
ntervention may have been doctor-led in the trial, whereas it is
urse-led in practice. Or, different diagnosticsmay be used than in
he trial. Therefore, it is important that the interventions in the
TA reflect how they will be embedded in clinical practice [6,7].
ariations in clinical practice patterns may not only influence the
ntervention, but may also affect the presentation and outcomes
f a disease, and in turn can affect the effectiveness and/or cost-
ffectiveness of a treatment. Also, trials often use relatively short
ime horizons that do not reflect the time horizon of the decision
roblem, which is generally longer. Time horizon is therefore a
actor thatmay impact the applicability of an HTA [10-12,21,22,32–
4]. Consequences may not be measured in a way that they are
pplicable to the decision problem. This may be caused by inter-
ediate endpoints or limited sample sizes that do not represent
he actual decision problem [10–12,22,32–34]. For example, only
urvival may be incorporated in an HTA, whereas adverse events
hat reduce quality of life are very important and therefore the
ecision problem is focused on maximizing quality adjusted life
ears (QALYs) [15]. Or, productivity losses due to absenteeismmay
ccur that were notmeasured in the trial. It is also important to be
ware of potential ripple effects that may occur, such as parents
ho experience productivity losses because of an ill child. Addi-
ional factors that may impact the applicability of an HTA are
atient use, health care professional use, and price and resource
se. Patient use may be influenced by compliance or uptake, and
ay be different in a trial than in daily practice [11,31–33]. Factors
hat may influence professional use include skills, experience, be-
ief, and incentives [31,32,34]. A useful division can be made here
etween whether and how a health care professional uses a tech-
ology. For example, a general practitioner may not prescribe a
ertain drug because he does not believe in its effectiveness. Or, a
urgeon may perform a new surgery differently than intended,
hich may hamper the effectiveness of the surgery, or may even
ause malpractice. Finally, price and resource use change over
ime andmay be different when a treatment is implemented than
t was during the trial [11,12,22,31,32]. For example, the price of a
iagnostic procedure may vary across settings and over time.
Framing the economic evaluation of trastuzumab in early
breast cancer
The reference case for the economic evaluation of trastuzumab in
early breast cancer is listed in Table 3. Various objectives and audi-
ences exist for the economic evaluation of trastuzumab in early
breast cancer. For example, the study can be performed to assist
decision makers in making a reimbursement decision, or it can be
performed for researchers to add to the existing knowledge. The per-
spective of the analysis depends on this audience and objective.
The population consists of women with HER2 positive early
breast cancer. The population in the trastuzumab trials is the re-
sult of very strict eligibility criteria, which will probably be less
strictly applied in the real world [26–28]. This could for example
lead to patients with a lower left ventricular ejection fraction re-
ceiving trastuzumab, possibly resulting in more cardiac adverse
events and presumably higher incremental cost effectiveness ra-
tio. The population could also be of a different age. The exact age
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781V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 7 7 – 7 8 4and left ventricular ejection fraction of the patient population de-
pends on the decision context.
With regard to the comparators, three different strategies of
trastuzumab treatment are evaluated in the existing trials. The
first regimen, referred to as theHERA regimen, consists of one year
trastuzumab, every 3 weeks after chemotherapy [25,27,29]. The
second regimen, referred to as the NSABP B31/NCCTG N9831 reg-
imen, consists of 1 year of trastuzumab weekly, concurrent with
chemotherapy [28]. The third regimen, called FinHer, consists of
nine weekly trastuzumab infusions, concurrent with chemother-
apy [26,30]. These three regimens as well as care as usual are all
relevant comparators.
As for clinical practice, trastuzumab is only effective in pa-
tients with a HER2-positive tumor, which is tested in the trials by
immunohistochemistry and, if indicated (HER2), also fluores-
cence in situ hybridization tests. There is a large variety world-
wide, however, which test is used in clinical practice and how test
results are interpreted [36]. This testing strategy should therefore
be considered in framing the economic evaluation. Additionally,
breast cancer care is very context-specific, and should therefore be
considered in the framing process.
The relevant time horizon for the analysis is lifetime. Because
beyond 5 years no data on trastuzumab in early breast cancer are
currently available from trials, the results need to be extrapolated
to assess long-term cost-effectiveness. The consequences that
should be considered are adverse events, costs and QALYs.
Because compliance or adherence is not expected to be rele-
vant for this problem, patient use is expected to be as it was in the
trials. Professional use on the other hand is expected to be rele-
vant. In the trials strict criteria are applied regarding when to stop
trastuzumab treatment if a patient shows cardiac reactions. It is
possible that professionals use the treatment differently and stop
trastuzumab sooner or later than outlined by stopping rules. Price
and resource used are context specific and should be adapted to
the relevant context.
Economic evaluations of trastuzumab in early breast cancer
The second literature search resulted in 87 full articles on the
economic evaluation of trastuzumab in early breast cancer. A total
of 11 publications met the inclusion criteria [37–47]. All studies
used decision-analytic modeling. The complete checklist for all
studies is listed in Table 3.
In most of the studies the objective, audience and perspective
ere specified. Five out of 11 studies used the population that was
ncluded in the trials for their economic evaluation [37–39,44,47].
he other six studies did incorporate the fact that the population is
ontext specific, through varying patient age [40–43,46] or weight
45]. No study investigated the impact of treating patients with a
orse or better left ventricular ejection fraction than included in
he trials, or incorporated the effect of patient age on cardiac prob-
ems. Liberato et al. [40] mentioned in their discussion that they,
ue to lack of data, could not fully consider the patient’s casemix.
No study examined all relevant comparators. Seven studies
ompared one trastuzumab regimen to care as usual [38,39,41,44–
7]. Two studies combined data from different trastuzumab regi-
ens into one intervention that was compared to care as usual
42,44]. More than one trastuzumab regimen was considered by
our studies [37,40,42,43]. In these studies the different trastu-
umab regimenswere all compared to care as usual, whichmeans
hat they did not calculate the cost-effectiveness of one strategy to
he next best strategy.
With regard to clinical practice, all studies defined breast can-
er care as it is organized in their country. Only two studies explic-
tly considered the HER2 test strategy [38,41]. All studies extrapo-
ated the trial data. The time horizon was lifetime in eight studies
38,41–47], two studies analyzed costs and effects over 15 years
[37,40]. One study used a not specified long-term time horizon [39].
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782 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 7 7 – 7 8 4Adverse events and costs were incorporated as consequences by
all studies. Eight studies used QALYs as the outcome measure of
interest [38–42,44,46,47]. The other three studies only examined
life years [37,43,45].
All studies incorporated patient use as it was observed in the
trials. Professional use that may result in different start and stop-
ping rules were not considered by any of the studies. Context-
specific price and resource use were incorporated by all studies.
Discussion
We reviewed the literature and developed a checklist containing
11 factors that assists in framing HTA studies in such a way that
they are applicable to the decision problem. Additionally, the
checklist can be used to determine the applicability of HTAs to
resource allocation decisions, and to adapt existing HTAs to make
them applicable to the decision problem.We illustrated the use of
the checklist by applying it to the case of trastuzumab in early
breast cancer.
The illustration of the checklist by applying it to the case of
trastuzumab in early breast cancer indicated that the checklist is
feasible. We have no reason to assume that the checklist is case-
specific and that it would not be feasible in other disease areas or
different types of interventions. Further use in other case studies
is necessary to confirm the feasibility and practical value of the
checklist. In the case of trastuzumab it was found that some fac-
tors were explicitly considered by all or amajority of studies (such
as the timehorizon), whereas other factorswere not considered by
any study (e.g., health care professional use and comparators) or
only few (e.g., clinical practice and population). The latter also
applies towork by our own group [47]. To improve the applicability
of HTAs for decisionmaking, it is important that all considerations
are explicitly stated, even when factors are not deemed relevant.
The checklist can then act as a guide to which factors should be
adapted in an HTA to make it applicable to the decision problem.
Although considering factors like time horizon (through extrapo-
lation) and patient population (through subgroup analyses) may
be common practice, other factors tend to be overlooked more
often. The factors that aremore commonly considered are also the
factors that are listed in handbooks or national pharmacoeco-
nomic guidelines (e.g., [4,21,22,48], and are well-known principles
of good economic evaluation. Factors that are not generally ac-
cepted principles of good economic evaluation seemedmore likely
to be overlooked. However, although it is recommended to include
all relevant comparators in an economic evaluation and compare
one strategy with the next best strategy [10,21], none of the eco-
nomic evaluations of trastuzumab considered all trastuzumab
regimens that are described in the literature. A reason why some
factors are not explicitly consideredmay be the absence of data. In
our opinion, the absence of data is no reason to not incorporate a
relevant parameter into the analysis [49].
The checklist can both guide the design and analysis of an HTA
for resource allocation decisions, and assess if existing HTAs are
applicable to the decision problem. The purpose of the checklist
will depend on the stage of the HTA. The first purpose of guiding
the design, or framing, of an HTA, is especially relevant in the
stage of developing the conceptual model [6]. For both trial-based
and model-based HTAs the use of the checklist aims to improve
the conceptual model validity by providing a systematic tool to
consider all factors and adapt the conceptual model to the deci-
sion problem. Of course, an HTA is only as accurate as its inputs,
and for factors like professional use no evidencemay be available.
Torrance et al. [6] introduced what-if analyses, which can be used
when data that are applicable to the decision context are lacking
but a policy decision is still needed. Inwhat-if analyses one should
anticipate on the fact that it may not be cost-effective to use (that
is: adopt and implement) a technology, for example because of thelow professional use. A possible solution for this is decision ana-
lytical modeling, as it allows for the synthesis of evidence from
different sources, and the exploration of the influence of devia-
tions between trial and practice on cost-effectiveness results [50].
When evidence on these factors is absent, experts could be con-
sulted and best/worst scenarios could be examined. Coveragewith
evidence development schemes are also useful to collect these
types of evidence, because patients in these schemes are being
monitored in the real world [51]. Additionally, the checklist could
assist in designing pragmatic trials for which the hypothesis and
study design are formulated based on informationneeded tomake
a decision [52]. This would assist in targeting research to the areas
where we need more evidence, which may result in the collection
of evidence that is more suited to the decision we need to make.
The second purpose of the checklist, assessing if a specific deci-
sion problem can be informed by an existing HTA, is relevant in a
later stage, when anHTA is readily available. In this stage it can for
example help decision makers assess if the HTA is useful for their
decision problem.We did not intend, however, to develop a check-
list in a sense that boxes can be ticked to calculate a score of
exactly how applicable an HTA is. Rather, we intended to provide
a systematic tool that can act as a guide towhich factors in anHTA
should be adapted tomake itmore applicable to the decision prob-
lem.Whether anHTA that, based on the checklist, was found to be
not fully applicable will lead to poor decisions is highly case-spe-
cific. It should be assessed if adapting the HTA to make it more
applicable, significantly affects the policy recommendation.
In the critical assessment of an HTA two questions are rele-
vant: 1) is themethodology is appropriate and the results are valid;
and 2) are the results applicable to the decision problem [10]. Com-
prehensive checklists exist to answer the first question, assessing
the quality of the HTA [8,10,18,19]. To date no checklist existed to
answer the secondquestion, assessing the applicability of theHTA
to the decision problem [8]. Our checklist aims to answer this sec-
ond question. It should be emphasized that our checklist should
not be used instead of, but complementary to the quality check-
lists. Although related, the problem of HTAs not being applicable
to the decision problem is conceptually different from HTAs not
being generalizable or transferable across clinical settings and ju-
risdictions [31,53,54]. Discount rate for example is important in
assessing transferability, as it differs across jurisdictions, whereas
the discount rate is not importantwhen assessing the applicability
of an HTA to the decision problem. On the other hand the relevant
time horizon of an analysis will not differ across jurisdictions, and
is therefore not listed as a factor in these checklists [31,54]. How-
ever, time horizon is an important factor when examining if an
HTA is applicable to the decision problem.Also, adverse events are
relevant in all jurisdictions and therefore not a factor that is con-
sidered with regard to transferability. In a trial, however, adverse
events may not have been measured although they are relevant
for the allocation decision. In examining the applicability of HTAs
to the decision problem it is therefore not only important if the
numbers are correct, but also if all relevant information is in-
cluded. Additionally, some of the factors in the proposed checklist
resemble part of a set ofmorally relevant questionswith respect to
assessing health technologies [55]. For example, one of these ques-
tions is what themorally relevant consequences of the technology
are. If these morally relevant consequences are relevant to the
decision problem, they should indeed be addressed when framing
theHTA.When using the proposed checklist, they should come up
at the consequences factor. The checklist and the set of questions
have a very different purpose, and therefore do not substitute but
complement each other.
In our application of the checklist we focused on economic eval-
uations.We believe, however, that the checklist is useful for HTAs in
general, considering both effectiveness and cost-effectiveness. The
checklistprovidesa tool to systematically frameanHTAinaway that
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783V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 7 7 – 7 8 4it is applicable for the decision problem, and to formally evaluate the
applicability of HTAs to the decision problem, which is currently
lacking [8]. Although the practical value of the checklist needs to be
revealed through future use, use of the presented checklist may im-
prove the applicability of HTAs to decision problems. Making HTAs
more applicable to the decision problem hopefully increases the im-
pact of HTA on policy decision making and on practice [56–58], and
may eventually lead to better policy decisions.
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